Assessment of serum levels of angiogenic factors in dizygotic twin infants with and without retinopathy of prematurity

Year 2013, Volume: 30 Issue: 1, 39 - 43, 26.03.2013

Selim Demir , Hüseyin Ortak Canan Aygün Özlem Yücel Mukadder Arslanbek Şükrü Küçüködük Ümit Beden

https://doi.org/10.5835/jecm.omu.30.01.010

Abstract

The aim of the study was to evaluate the plasma concentrations of vascular endothelial growth factor (VEGF-A), its soluble receptors VEGFR-1 and VEGFR-2, insulin like growth factor (IGF-1) and soluble Tie-2 in twin infants with and without retinopathy of prematurity (ROP). Eleven pairs of twin infants (total 22 infants) were included in the study: There were 11 infants with advanced stage ROP in the study group and 11 infants with no ROP in the control group. Before time-point measurements, the peripheral venous blood samples were first centrifuged, and the plasma was then stored at -70°C. The plasma concentrations of the angiogenic factors were measured by using high sensitivity enzyme-linked immunosorbent assay (ELISA) kits. The average gestational age of the infants at the time of birth and the time at which the serum samples were collected were 30.5±2.3 and 37.5±2.5 weeks, respectively. The average serum levels of all the angiogenic factors were higher in infants with ROP, but the differences were not statistically significant (p>0.05). In this study, serum samples of twins with and without ROP were evaluated simultaneously. The time of serum sampling in the study group corresponded to the period of phase 2 ROP. Therefore, there appeared to be no difference between the ROP group and the control group. 

Keywords

IGF-1, Retinopathy of prematurity, Tie-2, VEGF, VEGFR-1, VEGFR-2

References

• Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G.D., Isner, J.M., 1998. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 83, 233-240.
• Biglan, A.W., Brown, D.R., Macpherson, T.A., 1986. Update on retinopathy of prematurity. Semin Perinatol. 10, 187-195.
• Brock, R.S., Gebrekristos, B.H., Kuniyoshi, K.M., Modanlou, H.D., Falcao, M.C., Beharry, K.D., 2011. Biomolecular effects of JB1 (an IGF-I peptide analog) in a rat model of oxygeninduced retinopathy. Pediatr Res. 69, 135-141.
• Budd, S.J., Thompson, H., Hartnett, M.E., 2010. Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity. Arch Ophthalmol. 128, 1014-1021.
• Cai, J., Kehoe, O., Smith, G.M., Hykin, P., Boulton, M.E., 2008. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci. 49, 2163-2171.
• Chung, N.A., Makin, A.J., Lip, G.Y., 2003. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest. 33, 529-535.
• E,G., Cao, Y., Bhattacharya, S., Dutta, S., Wang, E., Mukhopadhyay, D., 2012. Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J Biol Chem. 287, 3029-3041.
• Early Treatment For Retinopathy Of Prematurity Cooperative Group, 2003. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 121, 1684-1694.
• Fiedler, U., Krissl, T., Koidl, S., Weiss, C., Koblizek, T., Deutsch, U., Martiny-Baron, G., Marmé, D., Augustin, H.G., 2003. Angiopoietin-1